- Trial Phase
- Phase 3 (completed for psoriasis); Phase 2b (ongoing for SLE)
- Time to Market
- NDA submission planned for Q4 2026 in plaque psoriasis; if standard FDA review (~10-12 months), potential approval in late 2027 or early 2028.
- Why 6/10
- The next hard, dated catalyst is the Phase 2b LUMUS topline data for envudeucitinib in systemic lupus erythematosus (SLE), expected in Q3 2026 (roughly 1-3 months). This is a potentially pivotal readout on the company's lead and only significant pipeline asset. ImpactScore is 6 (not 8) because the major Phase 3 psoriasis binary has already passed, and the SLE catalyst is Phase 2b rather than a registrational Phase 3.
The stock already surged ~6x from lows on the Phase 3 psoriasis win. The next binary is the SLE Phase 2b data in Q3 2026, which could expand the addressable market significantly if positive. However, Takeda's zasocitinib is a direct competitor also filing for psoriasis, and Alumis has no revenue — only cash through Q4 2027. Watch the SLE readout closely; a miss would erase a large portion of the thesis.
Price Chart
Executive Summary
Envudeucitinib is Alumis Inc.'s lead asset — a next-generation oral TYK2 inhibitor in development for plaque psoriasis and systemic lupus erythematosus (SLE). Phase 3 ONWARD trials in psoriasis met all endpoints with high statistical significance: ~65% of patients achieved PASI 90 (90% skin clearance) and >40% achieved complete clearance (PASI 100) at week 24. The company plans an NDA submission in Q4 2026 and has a Phase 2b SLE readout due in Q3 2026. Alumis raised $345M in January 2026, ending Q1 with $569.5M cash — enough into Q4 2027. The stock trades at ~$26, up from a ~$3 low, but analyst consensus is Strong Buy with a $40 mean target (~60% upside). Key risks include competition from Takeda's similarly positioned TYK2 inhibitor zasocitinib and the binary nature of the upcoming SLE data.
How It Works
Envudeucitinib is an oral pill that blocks a specific protein called TYK2, which acts like a "switch" for inflammation in the body. By inhibiting TYK2, the drug dampens several inflammatory pathways (including IL-23 and IL-17) that drive autoimmune diseases like psoriasis and lupus. It's more targeted than older JAK inhibitors, potentially offering efficacy closer to injected biologic drugs but in a convenient once- or twice-daily pill.
Trial Status
Two Phase 3 trials (ONWARD1 and ONWARD2) in moderate-to-severe plaque psoriasis completed with positive topline results announced January 6, 2026, showing statistical superiority over placebo and active-comparator apremilast. A Phase 2b trial in SLE (LUMUS) is active but not recruiting, with top-line data expected Q3 2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026: Phase 2b LUMUS topline data for envudeucitinib in systemic lupus erythematosus (SLE) — potentially pivotal readout
- Q4 2026: NDA submission to FDA for envudeucitinib in plaque psoriasis
- AAD medical meeting presentations of detailed Phase 3 data
- Potential FDA acceptance of NDA with PDUFA date in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALUMIS INC. 8-K ALMS ·Originating report